Publications by authors named "Run-Hua Wu"
Purpose: Obstructive sleep apnea (OSA) has been related to an increased risk of liver injury. Ferroptosis is a form of programmed cell death implicated in multiple physiological and pathological processes. This study aimed to explore the role of ferroptosis in chronic intermittent hypoxia (CIH)-induced liver injury as well as to uncover the underlying mechanisms using a CIH rat model.
View Article and Find Full Text PDFPurpose: Obstructive sleep apnea (OSA) and OSA-associated chronic intermittent hypoxia (CIH) have been suggested to be associated with increased risk of liver disease. Little is known about the biological pathophysiology and underlying molecular mechanisms. Here we use whole-genome expression profiling to explore the transcriptomic changes induced by CIH in rat liver.
View Article and Find Full Text PDFArticle Synopsis
- Chronic intermittent hypoxia (CIH) negatively impacts the metabolism of the drug theophylline in mouse liver, linked to changes in liver cell structure and function.
- Mice exposed to CIH for 12 weeks showed reduced theophylline metabolism rates and lower levels of liver cytochrome P450 compared to control mice.
- The findings suggest that CIH may inhibit drug metabolism in the liver through the downregulation of cytochrome P450, without significantly affecting serum transaminase levels.
Intermittent hypoxia and isoniazid plus rifampicin affect hepatic ultrastructure in mice.
Chin Med J (Engl)
December 2011
Background: Chronic intermittent hypoxia is the most important pathophysiologic feature of sleep apnea syndrome. The present study aimed to determine whether chronic intermittent hypoxia, which is associated with sleep apnea syndrome, can cause or increase damage to liver cell ultrastructure induced by isoniazid and rifampicin in mice.
Methods: Based on a 2 × 2 full factorial design consisting of two factors of chronic intermittent hypoxia and isoniazid plus rifampicin, 32 male C57B6J mice were randomized into the control group, the chronic intermittent hypoxia group, the isoniazid plus rifampicin group, and the chronic intermittent hypoxia + isoniazid plus rifampicin group.